Target intelligence / Profile preview

RNA, U6 small nuclear 754, pseudogene (RNU6-754P)

Target
RNU6-754P
Molecular classification
Other (Pseudogene), Non-coding RNA pseudogene
01

Overview

RNA, U6 small nuclear 754, pseudogene (RNU6-754P) is a non-protein-coding genetic sequence classified as a pseudogene of the U6 small nuclear RNA family[7][4][5]. Unlike the canonical *U6 small nuclear RNA*, which is a highly conserved and essential component of the spliceosome responsible for pre-mRNA splicing[3][1], RNU6-754P is a non-coding genomic segment that has evolved from U6 snRNA but has lost its original function. Pseudogenes such as RNU6-754P typically exhibit high sequence homology to their parent genes but lack biological activity due to mutations, truncations, or rearrangements, including direct repeats and disrupted structural motifs[5]. Pseudogenes, once considered "junk DNA," are now recognized for possible regulatory effects (e.g., antisense RNA, microRNA competition, ceRNA mechanisms), but these functions are context- and sequence-dependent and are not established for RNU6-754P specifically[6][7]. RNU6-754P itself is not associated with disease, drug interactions, or known biological functions; it serves as a marker of genome evolution and pseudogene generation in humans[5][4][7].

Other names
RNU6-754PRNA, U6 small nuclear 754, pseudogeneGeneCards identifiers (as listed): HGNC:47717, NCBI Gene:106481418, Ensembl:ENSG00000212468, plus historical IDs from GeneCards[7][4]
02

Mechanism of action

None. There are no drugs acting via RNU6-754P or established mechanisms of action for therapeutic modulation of this pseudogene[7][4].

03

Biological functions

None established for RNU6-754P as a pseudogene.General pseudogene functions may include: - Competing for microRNA binding (ceRNA mechanism)[6]Possible regulatory effects on parental gene expression (context-dependent; not established for this specific pseudogene)[6]No direct role in canonical splicing or known cellular processes[4][5][7]
04

Disease associations

None established for RNU6-754P as a pseudogene.Pseudogenes in general are increasingly studied for regulatory impact in cancer and other diseases, but there is no evidence that RNU6-754P is implicated[6][7][4].
05

Safety considerations

None known. No documented safety concerns or therapeutic challenges related to targeting RNU6-754P, as it is not a drug target[7][4].
06

Interacting drugs

None known. Pseudogenes like RNU6-754P are not direct drug targets and have no documented interacting drugs[4][7].
07

Biomarkers

None known. RNU6-754P is not established as a biomarker for patient selection or efficacy monitoring[7][4].

Beyond the preview

Go deeper on RNA, U6 small nuclear 754, pseudogene (RNU6-754P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U6 small nuclear 754, pseudogene (RNU6-754P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call